Holen Sie sich die Stockscreener-App
4.55
3.41%
0.15
Handel nachbörslich:
4.55
Schlusskurs vom Vortag:
$4.40
Offen:
$4.4
24-Stunden-Volumen:
31,156
Relative Volume:
0.23
Marktkapitalisierung:
$456.48M
Einnahmen:
$5.15M
Nettoeinkommen (Verlust:
$-65.35M
KGV:
-3.3704
EPS:
-1.35
Netto-Cashflow:
$-20.85M
1W Leistung:
-5.99%
1M Leistung:
-4.01%
6M Leistung:
+184.37%
1J Leistung:
+116.67%
1-Tages-Spanne:
$4.40
$4.6828
1-Wochen-Bereich:
$4.37
$4.9701
52-Wochen-Spanne:
$1.10
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Vergleichen Sie CLLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
4.55 | 441.43M | 5.15M | -65.35M | -20.85M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2022-05-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-03-06 | Herabstufung | Goldman | Neutral → Sell |
| 2019-10-30 | Fortgesetzt | Guggenheim | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Neutral |
| 2019-03-14 | Eingeleitet | William Blair | Outperform |
| 2018-12-19 | Eingeleitet | Goldman | Neutral |
| 2018-07-16 | Eingeleitet | Barclays | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2017-09-05 | Herabstufung | SunTrust | Buy → Hold |
| 2017-09-05 | Bestätigt | Wells Fargo | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-02-28 | Eingeleitet | Wells Fargo | Outperform |
| 2016-04-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | Eingeleitet | BofA/Merrill | Buy |
| 2015-04-20 | Eingeleitet | Jefferies | Buy |
| 2015-04-20 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Cellectis Adr Aktie (CLLS) Neueste Nachrichten
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView — Track All Markets
Clear Street initiates Cellectis stock with Buy rating on CAR-T potential - Investing.com
Working capital per share of Cellectis S.A. Sponsored ADR – NASDAQ:CLLS - TradingView — Track All Markets
European ADRs Inch Up As 3D Printer Materialise Leads Gains - Finimize
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Sahm
Arbitration ruling partially terminates Cellectis-Servier license agreement - Investing.com
European ADRs Stay Put As Novo Nordisk Slides - Finimize
12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Moligo and Cellectis show promise in non-viral gene editing method - Investing.com India
Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications - Sahm
Cellectis reports breakthrough in non-viral gene editing technique - Investing.com
Citizens maintains Cellectis stock rating with $8 target ahead of ASH update - Investing.com
European ADRs Slip As Gains And Losses Balance Out - Finimize
European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize
Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail
Barclays raises Cellectis stock price target to $8 on promising cancer therapy - Investing.com Philippines
Jefferies raises Cellectis stock price target to $6 after R&D day - Investing.com
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Operating cash flow per share of Cellectis S.A. Sponsored ADR – LSX:A14QZE - TradingView
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
A look into Cellectis ADR (CLLS)’s deeper side - Setenews
Cellectis’s SWOT analysis: gene therapy firm’s stock poised for growth? - Investing.com
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
European Stocks In The US Close The Week Mostly Steady - Finimize
European Equities Traded in the US as ADRs Fall in Friday Trading - 富途牛牛
Biotech And Tech Firms Drive Gains For European ADRs - Finimize
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
Finanzdaten der Cellectis Adr-Aktie (CLLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):